Skip to main content

Table 1 Demographic and clinical characteristics of the study population

From: The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study

Characteristic

Total

(N = 168)

DIH

(n = 20)

Non-DIH

(n = 148)

P-value

Age, years

53.4 ± 19.2

62.9 ± 17.1

52.1 ± 19.2

0.018

Sex, male

111 (66.1)

11 (55)

100 (67.6)

0.267

Body mass index, kg/m2

21.2 ± 3.2

20.2 ± 3.6

21.4 ± 3.1

0.215

Charlson comorbidity index score

0.48 ± 0.67

0.80 ± 0.83

0.43 ± 0.63

0.042

Chronic liver disease

14 (8.3)

5 (25.0)

9 (6.1)

0.004

Chronic alcoholic

8 (4.8)

3 (15.0)

5 (3.4)

0.022

Diabetes mellitus

28 (16.7)

3 (15.0)

25 (16.9)

0.832

Cavitary lesion evident in chest X-ray

66 (39.3)

7 (35.0)

59 (39.9)

0.677

Frequency of sputum smear/culture

6.7 ± 3.1

6.6 ± 2.5

6.7 ± 3.1

0.968

Interval of sputum smear/culture, days

41.4 ± 18.3

41.4 ± 17.9

41.4 ± 18.4

0.975

Positive sputum AFB smear

80 (47.6)

10 (50.0)

70 (47.3)

0.821

Positive sputum AFB culture (liquid)

162 (96.4)

19 (95.0)

143 (96.6)

0.715

Positive sputum AFB culture (solid)

156 (92.9)

20 (100)

136 (91.9)

0.188

Positive sputum TB PCR (n = 65)

52 (80.0)

8 (80.0)

44 (80.0)

0.279

  1. Data are presented as n (%) or means ± SDs. DIH drug-induced hepatotoxicity, AFB acid-fast bacilli, PCR polymerase chain reaction